share_log

Truist Securities Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $160

Truist Securities Maintains Buy on CRISPR Therapeutics, Lowers Price Target to $160

Truist 證券維持對CRISPR Therapeutics的買入,將目標股價下調至160美元
Benzinga ·  2023/12/11 11:31

Truist Securities analyst Joon Lee maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and lowers the price target from $220 to $160.

Truist Securities分析師李俊維持CRISPR Therapeutics(納斯達克股票代碼:CRSP)的買入,並將目標股價從220美元下調至160美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論